Previous close | 234.80 |
Open | 235.10 |
Bid | 237.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 234.00 - 237.80 |
52-week range | 212.90 - 293.55 |
Volume | |
Avg. volume | 1,472,649 |
Market cap | 191.277B |
Beta (5Y monthly) | 0.16 |
PE ratio (TTM) | 16.56 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 9.60 (4.05%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
SOUTH SAN FRANCISCO, Calif., May 16, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase Ib clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes. The study found that a once-weekly subcutaneous injection of CT-388 over 24 weeks resulted in significant weight loss in healthy adults with obesity compared to placebo. The weight loss achieved with CT-388 was
Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p < 0.001) At week 24, 100% of CT-388 treated participants achieved >5% weight loss, 70% achieved >15% and 45% achieved >20% weight loss In a subgroup with pre-diabetes at baseline, CT-388 treatment normalised glycemia in all patients, indicating its strong impact on glucose homeostasisNo new or unexpected safety signals were det
More than half of all U.S. cervical cancer patients are underscreened1, which makes reducing barriers to sample collection and increasing access to screenings crucial to ultimately helping eliminate this deadly disease.Each year in the U.S., more than 13,000 patients are diagnosed with cervical cancer and approximately 4,000 die from this preventable disease, caused by HPV infection.1Roche’s human papillomavirus (HPV) self-collection solution will improve access to testing by providing women the